LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study seeks to assess the effects of lisdexamfetamine (trademark name: Vyvanse; LDX) on
executive function and prefrontal cortex activation in menopausal women ages 45-57, who
report subjective cognitive difficulties. This protocol will recruit women from Dr.
Epperson's ongoing study, Protocol #812470, to examine the impact of LDX on brain activation
during performance of cognitive tasks specifically probing prefrontal cortex function.